Crohn's disease and ulcerative colitis are chronic autoimmune disorders associated with major clinical and economic burden. The American College of Gastroenterology (ACG) recently released updates to their clinical guidelines for the Management of Crohn's Disease (CD) and Ulcerative Colitis (UC) in Adults. Both guidelines incorporate available evidence to provide recommendations for the treatment and prevention of complications associated with inflammatory bowel disease (IBD). The objective of this webinar is to highlight guideline updates and provide suggestions for application of the recommendations into practice and payer policy.

IgA nephropathy is an autoimmune, progressive, chronic kidney disease characterized by pathogenic IgA accumulation and immune complex formation in the glomerulus, causing inflammation and progressive kidney damage. The webinar will review IgA nephropathy and clinical outcomes from Phase 2 and 3 trials of an investigational product that is under clinical evaluation for the treatment of primary IgA nephropathy in adults. Efficacy and safety have not yet been established.

Advance understanding of the importance of frequent monitoring risk level of pulmonary arterial hypertension (PAH) and right heart monitoring. Explore and discuss the importance of timely escalation of therapies in the treatment of PAH. Participants will learn about the significant role risk stratification plays in informing providers' treatment decisions, as well as the importance of right heart and hemodynamic considerations in conjunction with risk assessment.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

This webinar highlights an introduction to Scholar Rock, an emerging biopharmaceutical company, and provides an overview of the Spinal Muscular Atrophy (SMA) disease landscape, remaining unmet needs in SMA, and apitegromab clinical data.

Pre-Approval Information Exchange presentation for investigational revumenib, including a clinical overview, burden of disease, and disease background for pediatric and adult patients with NPM1-mutated relapsed or refractory acute myeloid leukemia.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

Join the inaugural event of AMCP’s AI LINK Interest Group and explore how artificial intelligence is transforming managed care pharmacy. We’ll dive into why standardized frameworks are essential to evaluate AI-driven solutions and how transparent, interoperable tools can help payors make informed, safe, and efficient coverage decisions. Not in an AMCP LINK yet? AMCP members can sign up now. 

Guest Experts: 

• Brenton Hill, JD, MHA - CHAI 
• Keith Kallmes - Knested Knowledge 
• Adam Colborn, JD - AMCP

To participate in eLearning Day, you must register for each session individually by clicking the "Register" tab above and selecting the sessions you would like to attend.

11–12pm ET

[eLD 1] Advancing Precision Medicine in Breast Cancer: Targeted Therapies and the Role of Managed Care Pharmacy

This activity is supported by an independent medical education grant from AstraZeneca Pharmaceuticals, Daiichi Sankyo, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Precision medicine is transforming the landscape of breast cancer care by enabling treatment strategies tailored to the molecular characteristics of each patient's tumor. This session will explore the impact that early biomarker testing and screening may have on breast cancer treatment efficacy, patient outcomes, and minimizing unnecessary side effects. In addition, faculty will highlight how managed care pharmacists are incorporated throughout the patient journey, from addressing reimbursement challenges, participating in molecular tumor boards (MTBs), and improving access to biomarker-driven treatments through formulary management and value-based contracting. Through a combination of clinical insights and managed care perspectives, attendees will learn how to support the integration of precision medicine into earlier lines of treatment and optimize the delivery of care for breast cancer patients.

1-2pm ET

[eLD 2] Preventative Health in Action: Advancing Shingles Vaccination in Special Populations

This activity is supported by an independent medical education grant from GSK.

Herpes zoster, also known as shingles, remains a significant public health concern in the United States, particularly among aging and immunocompromised populations. Each year, approximately one in three Americans will develop shingles. The risk increases substantially after age 50.

As healthcare shifts toward a value-based and preventative care model, managed care pharmacists have a critical opportunity to improve vaccination rates through benefit design, care coordination, and patient engagement strategies. This education session will provide pharmacists with updated knowledge on the prevalence and burden of shingles, current immunization guidelines, and equip them with actionable managed care strategies to promote equitable access and affordability.

5-6pm ET Satellite Symposium

Leveraging the Latest Treatment Updates to Advance Managed Care Decision-Making in Eosinophilic Esophagitis: A 'Mock P&T' Initiative to Unlock the Potential of Novel Therapies

Sponsored and presented by PRIME Education, LLC, separate registration required, click here to register.

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Eosinophilic esophagitis (EoE) is a chronic inflammatory condition that significantly impacts patient health, psychosocial well-being, and quality of life. This condition is also associated with a substantial economic burden, with an estimated healthcare cost of $1.32 billion in 2024 dollars after accounting for inflation. Historically, management of EoE has relied on patient adherence to restrictive dietary regimens and/or off-label use of pharmacologic agents developed for other indications. Fortunately, advances in clinical research have led to the development and FDA approvals of new EoE-specific therapies and the subsequent publication of updated clinical guidelines. With this rapidly evolving landscape, managed care professionals are challenged to stay up to date with the latest clinical data to support evidence-based patient selection and formulary design to optimize quality care and outcomes for patients with EoE. Inadequate payer knowledge of the latest therapeutic approvals and clinical evidence can lead to restrictive payer policies that derail appropriate access to newer therapies. Timely education is needed for managed care professionals so they may close the gaps in unmet treatment needs for patients with EoE. By equipping managed care professionals with evidence-based educational support, payers in these key decision-making roles can champion improved access to treatment modalities that advance quality care and optimize clinical outcomes for patients with EoE.

To Join Live Sessions:

• Join live sessions from your Pending Activities list by clicking the individual session name and then "Take Course." OR
• Click the "join session" link in the registration confirmation email; a separate email will be sent for each session you register for.